Showing 1,461 - 1,480 results of 32,185 for search '(( 5 ((fold decrease) OR (nn decrease)) ) OR ( 50 ((we decrease) OR (a decrease)) ))', query time: 1.06s Refine Results
  1. 1461
  2. 1462
  3. 1463
  4. 1464
  5. 1465
  6. 1466
  7. 1467
  8. 1468
  9. 1469
  10. 1470
  11. 1471
  12. 1472
  13. 1473

    Complete maps of RBD mutations that escape LY-CoV1404 binding. by Tyler N. Starr (3276999)

    Published 2022
    “…“Escape fraction” represents the fraction of cells with that mutation that are sampled in an antibody-escape bin representing 10-fold decreased binding (<a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1010951#ppat.1010951.s008" target="_blank">S8A Fig</a>). …”
  14. 1474

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  15. 1475

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  16. 1476

    Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

    Published 2024
    “…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
  17. 1477
  18. 1478
  19. 1479
  20. 1480

    Anthelmintics Derived from the Kinase Inhibitor SGI-1776 for the Treatment of Gastrointestinal Worm Infections by Mostafa A. Elfawal (22430138)

    Published 2025
    “…The unexpected SAR of compound <b>15</b> can be explained by computational modeling. We demonstrate the efficacy of optimized compound <b>50</b> as a new oral anthelmintic, which demonstrated better gut restriction properties and significantly reduced the fecundity of T. muris whipworm adults in infected mice. …”